Technical Analysis for KURA - Kura Oncology, Inc.

Grade Last Price % Change Price Change
grade C 15.69 -0.06% -0.01
KURA closed down 0.06 percent on Tuesday, December 10, 2019, on 78 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
See historical KURA trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
200 DMA Resistance Bearish -0.06%
Shooting Star Candlestick Bearish -0.06%
Lizard Bearish Bearish Day Trade Setup -0.06%
Pocket Pivot Bullish Swing Setup -0.06%
Upper Bollinger Band Touch Strength -0.06%
Crossed Above 20 DMA Bullish 0.51%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.51%
Pocket Pivot Bullish Swing Setup 0.51%
Older signals for KURA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Kura Oncology, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule drug candidates that target cell signaling pathways, which drive the progression of various cancers. The company's lead drug candidate, tipifarnib, an inhibitor of protein farnesylation is in Phase II clinical trials used for the treatment of solid tumors, including thyroid, head, neck, urothelial carcinomas, and salivary cancers with HRAS mutations, as well as patients with peripheral T-cell lymphoma. Its product pipeline also comprise preclinical programs, such as orally-available small molecule inhibitors of extracellular-signal-regulated kinases 1 and 2, such as KO-947 and other backup compounds for the treatment of patients with activating mutations in or other dysregulation of the mitogen-activated protein kinase signaling pathway consisting of mutations in KRAS, BRAF, and NRAS; and orally available, small molecule inhibitors of the menin-MLL interaction for the treatment of patients with acute leukemias involving translocations or partial tandem duplications of the mixed lineage leukemia (MLL) gene. The company was founded in 2014 and is headquartered in La Jolla, California.
Medicine Cancer Oncology Solid Tumors Cancers Cell Signaling Signal Transduction Oncogenes Benzamides Ras Subfamily Blood Cancers Braf Kras

Is KURA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 21.42
52 Week Low 12.3
Average Volume 244,790
200-Day Moving Average 16.43
50-Day Moving Average 14.93
20-Day Moving Average 15.30
10-Day Moving Average 15.56
Average True Range 0.67
ADX 15.99
+DI 25.76
-DI 12.86
Chandelier Exit (Long, 3 ATRs ) 14.67
Chandelier Exit (Short, 3 ATRs ) 16.40
Upper Bollinger Band 16.09
Lower Bollinger Band 14.50
Percent B (%b) 0.75
BandWidth 10.40
MACD Line 0.15
MACD Signal Line 0.12
MACD Histogram 0.03
Fundamentals Value
Market Cap 313.61 Million
Num Shares 20 Million
EPS -1.53
Price-to-Earnings (P/E) Ratio -10.25
Price-to-Sales 0.00
Price-to-Book 6.41
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.77
Resistance 3 (R3) 16.87 16.61 16.59
Resistance 2 (R2) 16.61 16.33 16.56 16.53
Resistance 1 (R1) 16.15 16.17 16.02 16.05 16.47
Pivot Point 15.89 15.89 15.83 15.84 15.89
Support 1 (S1) 15.43 15.61 15.30 15.33 14.91
Support 2 (S2) 15.17 15.45 15.12 14.85
Support 3 (S3) 14.71 15.17 14.79
Support 4 (S4) 14.61